IBBQInvesco Nasdaq Biotechnology ETF
Tracks the Nasdaq Biotechnology Index.
By Invesco · Launched 2021
Annual Cost
0.19%
#870 of 6,040 · low cost
Fund Size
$96M
#3,132 of 6,040 · mid-size
Return (1Y)
+49.6%
Track Record
5 years
#2,351 of 6,040 · seasoned
Performance
Total-return NAV · USDGrowth of $10,000
$14,642+46.4%
Total-return NAV, USD. Net of fund fees, before tax.
What's inside
How Beacon categorizes this fundAsset class
EquityRegion
North americaCap
Multi cap
Strategy
Index tracking
Sector
Health careFocus
Biotech & Genomics
Index tracked
Nasdaq Biotechnology Index
Holdings
By weightConcentration
Top 10 holdings = 63.3% of fundconcentrated
Invesco Private Prime Fund
14.3%
Gilead Sciences, Inc.
9.6%
Vertex Pharmaceuticals Inc.
9.3%
Amgen Inc.
9.1%
Regeneron Pharmaceuticals, Inc.
6.0%
Invesco Private Government Fund
5.5%
Alnylam Pharmaceuticals, Inc.
3.3%
Insmed Inc.
2.4%
Biogen Inc.
2.1%
argenx SE
1.7%
Asset allocation
Stocks
100.0%
Cash
0.0%
By sector
Healthcare
100.0%
Risk profile
Last 12 months · Sharpe & Sortino need 3+ yearsVolatility (1Y)
21.5%High
Year-on-year price swings
Max drawdown
-38.0%Severe
Worst peak-to-trough loss
Sharpe (3Y)
0.82Decent risk-adjusted returns
Sortino (3Y)
1.20Good downside protection
Listing
- Exchange
- NASDAQ Global Select Market
Full fund details
- Objective
- Tracks the Nasdaq Biotechnology Index.
- Strategy
- Invests at least 90% of total assets in securities that comprise the Nasdaq Biotechnology Index, which includes large-, mid-, and small-cap companies in the biotechnology and pharmaceuticals sectors. Employs full replication methodology to track the index, concentrating investments in biotechnology and pharmaceutical industries.
- Inception date
- June 11, 2021
- Fund family
- Invesco
Similar funds
Same asset class, closest by strategy & exposureNext steps
Save IBBQ to compare it with other funds, or start building a portfolio.
Data updated on 2026-09-18